Cargando…
Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085895/ https://www.ncbi.nlm.nih.gov/pubmed/36913139 http://dx.doi.org/10.1007/s40262-023-01236-4 |
| _version_ | 1785022026114662400 |
|---|---|
| author | Agersnap, Mikkel Askjær Sonne, Kim Knudsen, Kim Mark Sulowicz, Wladyslaw |
| author_facet | Agersnap, Mikkel Askjær Sonne, Kim Knudsen, Kim Mark Sulowicz, Wladyslaw |
| author_sort | Agersnap, Mikkel Askjær |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10085895 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100858952023-04-12 Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment Agersnap, Mikkel Askjær Sonne, Kim Knudsen, Kim Mark Sulowicz, Wladyslaw Clin Pharmacokinet Correction Springer International Publishing 2023-03-13 2023 /pmc/articles/PMC10085895/ /pubmed/36913139 http://dx.doi.org/10.1007/s40262-023-01236-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Agersnap, Mikkel Askjær Sonne, Kim Knudsen, Kim Mark Sulowicz, Wladyslaw Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title | Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title_full | Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title_fullStr | Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title_full_unstemmed | Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title_short | Correction to: Pharmacokinetics, Safety, and Tolerability of Glepaglutide, a Long-Acting GLP-2 Analog, in Subjects with Renal Impairment |
| title_sort | correction to: pharmacokinetics, safety, and tolerability of glepaglutide, a long-acting glp-2 analog, in subjects with renal impairment |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085895/ https://www.ncbi.nlm.nih.gov/pubmed/36913139 http://dx.doi.org/10.1007/s40262-023-01236-4 |
| work_keys_str_mv | AT agersnapmikkelaskjær correctiontopharmacokineticssafetyandtolerabilityofglepaglutidealongactingglp2analoginsubjectswithrenalimpairment AT sonnekim correctiontopharmacokineticssafetyandtolerabilityofglepaglutidealongactingglp2analoginsubjectswithrenalimpairment AT knudsenkimmark correctiontopharmacokineticssafetyandtolerabilityofglepaglutidealongactingglp2analoginsubjectswithrenalimpairment AT sulowiczwladyslaw correctiontopharmacokineticssafetyandtolerabilityofglepaglutidealongactingglp2analoginsubjectswithrenalimpairment |